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Abstract
Strategies to enhance, suppress, or qualitatively shape the immune response are of importance for 
diverse biomedical applications, such as the development of new vaccines, treatments for 
autoimmune diseases and allergies, strategies for regenerative medicine, and immunotherapies for 
cancer. However, the intricate cellular and molecular signals regulating the immune system are 
major hurdles to predictably manipulating the immune response and developing safe and effective 
therapies. To meet this challenge, biomaterials are being developed that control how, where, and 
when immune cells are stimulated in vivo, and that can finely control their differentiation in vitro. 
We review recent advances in the field of biomaterials for immunomodulation, focusing 
particularly on designing biomaterials to provide controlled immunostimulation, targeting drugs 
and vaccines to lymphoid organs, and serving as scaffolds to organize immune cells and emulate 
lymphoid tissues. These ongoing efforts highlight the many ways in which biomaterials can be 
brought to bear to engineer the immune system.
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1. INTRODUCTION
The immune system plays a critical part in the health of organisms, from invertebrates to 
humans, and can be either a cure or cause of disease. Traditionally, the immune system has 
been viewed by biomedical engineers as an adversary to the effective design of biomaterials, 
as an organizer of the host response that shortens the lifespan and function of implants or the 
mediator of rapid clearance of systemically administered drug carriers. However, interest is 
increasingly focusing on engineering biomaterials [in the form of solid implants, hydrogels, 
microparticles, or nanoparticles (NPs)] to rationally control the immune system by 
enhancing or suppressing immune reactions in an antigen-specific or -nonspecific manner to 
treat disease or overcome adverse immune situations. In addition, as in other areas of cell 
biology, biomaterials can be designed as tools to control tissue, cell, and molecular 
interactions that regulate immune cells in order to shed new light on the functioning of the 
immune system. This new area of immune engineering using biomaterials is generating 
promising new strategies for vaccination, cancer immunotherapy, treatment of autoimmune 
disorders, and establishing tolerance to organ transplants. In this review, we discuss some of 
the important directions that scientists have pursued in using biomaterials to direct the 
functions of the immune system.
2. EFFECTS OF BIOMATERIALS ON IMMUNE CELLS, AND 
IMMUNOMODULATION USING PARTICULATES, PROTEIN CHEMISTRY, 
CONTROLLED RELEASE, AND BIOMIMICRY
Research into bio-inspired materials and endogenous mechanisms of immune stimulation 
have shown tantalizing results for developing efficacious vaccines and therapies for curing 
diseases. In this section, we discuss immune-engineering approaches utilizing biomimetic 
presentation, cell targeting, the controlled release of immunomodulators, and the properties 
of endogenous materials to stimulate or suppress the immune response. The body of work 
presented here serves as an introduction to these topics and seeks only to emphasize recent 
developments in these fields and the key advancements that have shown these approaches to 
be of possible use in clinical therapies.
2.1. Protein-Based Approaches for Effective Immunization
The biomimetic presentation of synthetic antigens via self-assembled fibrillar peptides 
without the aid of adjuvants has been shown to elicit strong long-lasting antibody responses 
to vaccines and immunotherapies (1). Collier and coworkers (2) showed that a fusion protein 
of a self-assembling β-sheet fibrillar peptide, Q11, and the antigenic ovalbumin (OVA) 
peptide OVA323--339, maintained anti-OVA antibody responses in mice for more than 1 
year. They also showed that the sustained immune response relied on CD4+ T cells, and that 
the Q11 peptide by itself was nonimmunogenic, even when delivered in Complete Freund’s 
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Adjuvant. It was later shown that the multivalent fibrillar conformation of the presented 
fusion protein was critical to sustaining the immune response (3). Further, durable antibody 
responses against a malaria epitope (4) and high-affinity B cell responses (without systemic 
inflammation) (5) have also been shown utilizing these epitopes. Finally, using 
supramolecular assemblies, a variety of structurally complex proteins have also been shown 
to retain their structure and function (6, 7). Thus, from these studies it is evident that fibrillar 
self-assembled proteins, although not inflammatory on their own, are potent adjuvants for 
long-term adaptive immunity (3).
The engineered self-assembled peptide approach has been shown to be effective in 
generating long-term immunity against several model antigens including OVA, green 
fluorescent protein, and malaria peptides (1, 2, 4, 6, 8). In the last two years, these constructs 
have also been shown to induce, in dendritic cells (DCs), high expression of the 
proinflammatory activation markers CD80 and CD86, and also to induce antigen-specific 
differentiation of T cells into T follicular helper cells and B cells into germinal center cells 
(5). This activation led to the production of high-titer, high-affinity immunoglobulin G (IgG) 
antibodies in vivo that crossreacted with the native protein antigen and were neutralizing in 
an in vitro influenza hemagglutination inhibition assay to a greater extent than was induced 
by alum and to an equal extent with Complete Freund’s Adjuvant (5).
Another interesting self-assembly approach that aimed to overcome the low immunogenicity 
of the highly conserved ectodomain of the influenza matrix protein 2 (M2e) was to form 
protein nanoclusters of self-assembled conformation-stabilized M2e tetramers (tM2e) (10). 
Intranasal vaccination of mice with the protein nanoclusters resulted in 100-fold higher 
levels of serum M2e–specific IgG when compared with mice immunized with soluble tM2e. 
Furthermore, activation of antigen-specific T cell cytokine release was observed, and the 
adoptive transfer of serum from immunized mice conferred complete protection against 
lethal challenge with homo- as well as heterosubtypic viruses, likely through the delivered 
antigen-specific antibodies in the transferred serum. Interestingly, incorporating Toll-like 
receptor (TLR)-9 ligands (CpG oligonucleotides) as an adjuvant did not provide additional 
benefit to the protein nanoclusters. Taken together these studies are examples of the 
innovative use of the principles of protein chemistry to develop protein-based vaccines that 
consist of both the antigen against which the immune response is directed plus the adjuvant 
or immunomodulatory ability of the formulation, without the need for an exogenous 
biomaterial. Thus, these approaches are unique in their elegant simplicity and they 
exemplify the use of protein-based biomaterials that have multifunctionality.
2.2. Effects of Biomaterials on Dendritic Cells
Traditionally, vaccine-delivery and tissue-engineering approaches have used biomaterials as 
vehicles for delivery or as support structures. Thus, it is important to understand how 
biomaterials affect key cells that direct immune responses, specifically DCs. Furthermore, 
elucidating how key properties of biomaterials---such as surface chemistry, surface energy, 
surface topology, and the size and shape of a material---influence responses by DCs offers 
opportunities to use the biomaterial component of a device for immunomodulation. 
Babensee and coworkers (11, 12) have shown a differential effect on the phenotype of DCs 
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derived from human peripheral blood that depends on the biomaterial used to treat them in 
vitro. Treating DCs with alginate and agarose films did not stimulate DCs above that of DCs 
cultured on tissue culture polystyrene controls; however, treating DCs with poly(lactic-co-
glycolic) acid (PLGA) or chitosan films supported DC maturation, which was shown by 
increased surface expression of the proinflammatory markers CD80, CD86, CD83, HLA-
DQ, and CD44; allostimulatory capacity; and a variety of released proinflammatory 
cytokines (11, 13). Mixed lymphocyte reactions showed that DCs treated with PLGA and 
chitosan films supported higher levels of T cell proliferation when compared with those of 
untreated, immature DCs (iDCs); also, DCs treated with hyaluronic-acid films induced 
lower levels of T cell proliferation when compared with iDCs. Recently, it was shown that 
culturing DCs pretreated with these different biomaterials affected the phenotype and 
polarization of co-cultured autologous T cells.(12) Interestingly, treatment of DCs with 
agarose films that had an added model antigen (OVA) induced the expansion of 
CD4+CD25+Foxp3+ T regulatory cells (Tregs) in autologous DC--T cell cocultures. 
Furthermore, in this coculture, agarose treatment induced the release of interleukin 
(IL)-12p70 and IL-10 at higher levels when compared with treating DCs with other 
biomaterial films and OVA, suggesting, respectively, Th1 and Th2 polarization. Treatment 
with PLGA film and OVA induced in DCs the release of interferon-γ (IFN-γ) at higher 
levels when compared with those observed for cocultures with iDCs or DCs treated with all 
other biomaterial films (12). In total, these results indicate that to intelligently design 
vaccines and clinical therapies, the biocompatibility criterion should include an analysis of 
the immunomodulatory characteristics of the material.
A complete understanding of the mechanisms by which DCs recognize and respond to 
biomaterials remains to be elucidated. Likely mechanisms include receptor-mediated 
processes known to be important in host responses to biomaterials, which are directed 
through biomaterial-adsorbed cell-adhesive proteins, and complement-activation fragments 
using receptors on leukocytes, such as integrins and complement receptors. However, 
additional interactions can be considered, as suggested by the mechanisms by which DCs 
recognize pathogens and sense tissue damage or danger. Such mechanisms include pattern-
recognition receptors such as TLRs and C-type lectin receptors. Many endogenous TLR 
ligands are proteins known to adsorb to biomaterials, such as fibrinogen and fibronectin 
(14); also, such proteins are glycosylated (15), suggesting the potential for responses 
mediated by C-type lectin receptors. Both the adsorption of complement-activation 
fragments and other danger signals to biomaterials have been implicated in the response of 
DCs to biomaterials (16). Recent research using MyD88- and Tlr-knockout mice 
demonstrated that DCs use TLR2, TLR4, and TLR6 for their responses to a diverse set of 
biomaterials (17). Also recently, β2 integrins have been shown to play a part in mediating 
DC adhesion and response to biomaterials (18). These studies implicate extracellular matrix 
proteins adsorbed to biomaterial surfaces as being integral to DC response to these proteins. 
DCs cultured on collagen or vitronectin substrates released higher levels of IL-12p40, but 
DCs cultured on albumin- or serum-coated plates generated higher amounts of IL-10 (19). 
These results imply that intelligently engineered biomaterials may guide the presentation, 
orientation, or conformation of adsorbed proteins in such a way that the combination 
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products in which they are used will induce either DC tolerance or activation to codelivered 
antigen.
Biomaterials have been shown to have an adjuvant effect that enhances the immunogenicity 
of antigens. Adsorption of OVA to phagocytosable microparticles, or onto PLGA scaffolds, 
has been found to support an antibody-mediated immune response that was maintained for 
longer than 16 weeks and was seen to be predominantly of a “Th2” type,, as indicated by 
IgG1 antibody titers (20). In an experiment comparing two formulations that used equivalent 
amounts of polymer, antigen loading, and release rates, it was found that delivery of antigen 
by an implanted PLGA scaffold induced an elevated antigen-specific humoral response with 
greater longevity than did an injection of microparticles, (21). It was hypothesized that 
danger signals released from tissue damage during surgery caused the enhanced immune 
response to antigen released from the implanted scaffolds. This was supported by the fact 
that HMGB1, a potent danger signal, was found in higher concentrations in exudates from 
subcutaneously implanted PLGA scaffolds with incorporated OVA (22). This result suggests 
the possible role of an adjuvant effect caused by danger signals induced by the biomaterial. 
Supporting the differential effects observed in vitro of PLGA and agarose in inducing, 
respectively, the maturation of DCs or not, PLGA scaffolds delivering the model antigen, 
OVA, acted as adjuvants in the humoral OVA-specific immune response, but agarose 
delivery of OVA did not (23). Hence, the selection of biomaterials can differentially affect 
the adaptive immune response to a co-delivered antigen. Furthermore, the in vitro 
assessment of the effects of biomaterials on DC maturation has been validated as predicting 
the in vivo adjuvant effect of the biomaterial with the co-delivered antigen.
2.3. Nano- or Microparticle Engineering for Immune Outcomes
Nano- or microparticle engineering can be used to affect many particle characteristics to 
achieve a desired immune effect, including particle-surface chemistry, size, and shape. 
Particle shape plays a significant part in extracellular trafficking, recognition by immune 
cells, and in the intracellular processing of particles (24). Due to physiological differences in 
processing, the shapes of nano- and microparticles have been shown to have roles in 
targeting drug delivery for cancer therapies (25), vaccine development (16, 26), and in 
chronic inflammation (27). The hypothesized mechanisms for how particle shape influences 
immune phenotype include how the particle interacts with the endothelium (28--30), spleen 
(31), liver (32), and lymphatic system (33). For example, spherical particles in vessels do 
not deviate from their laminar-stream motion unless perturbed externally (34). Conversely, 
ovoid and asymmetrical particles tumble, spin, and break their streamline in the vasculature 
and, thus, tend to marginate toward the walls of blood vessels (28, 29). This difference in 
flow behavior could be utilized to deliver endothelial therapies or to better transport particles 
in the bloodstream.
The clearance of particles can also be drastically affected by particle shape. The spleen 
filters particulates of 200 nm or smaller from the bloodstream; thus, if particles are rod or 
ovoid in shape and have a diameter or width that is less than 200 nm but a length of several 
microns they could pass through the spleen (33). Additionally, the extent of phagocytosis 
has been shown to depend heavily on particle shape, with longer, thinner (worm-like) 
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morphologies leading to phagocytosis that is 50 times lower than that of spherical 
particles(35). Further study has shown that elliptical disk particles avoid phagocytosis in a 
manner that depends on their orientation (36). Particles with a high aspect ratio have been 
shown to be internalized more slowly than those with a low aspect ratio (37--39). Studies 
have shown that elongated particles are trafficked toward the nucleus and are oriented 
tangentially when compared with spherical particles, which are trafficked quickly and 
exhibit hexagonal packing in the cell (38, 40). Additionally, budding, or highly textured, 
microparticles have been shown to activate neutrophils significantly more than smooth 
particles (41) (Figure 2 a–b). Further, budding particles were more readily phagocytosed 
than smooth particles and induced more lipid-raft recruitment to the phagosome. Budding 
particles have also been found to induce stronger IL-1β secretion than smooth particles 
through activation of the NLRP3 inflammasome (41).
Intravenously injectable microparticle therapies must use particle sizes that are smaller than 
1.5 µm in order for the particles to not clog capillaries (37, 42). Additionally, particle size 
has been shown to drastically alter the circulation times of injected therapies (25) and to 
alter how particles are transported through the body---i.e., through the lymphatic or vascular 
system (43). In general, small particles are less likely to be taken up by macrophages than 
large ones due to the fact that the proper geometric configuration for efficient complement 
activation can be achieved less easily on the more highly curved surfaces of the smaller 
particles than on the surfaces of larger ones (43--45). For optimal circulation times it has 
been found that NPs should have diameters between 20 and 100 nm (46, 47). At sizes 
smaller than 20 nm, NPs are filtered out by the kidney (48); at sizes larger than 100 nm, 
particles begin to be sequestered by sinusoids in the spleen and fenestrae of the liver (49). 
Particles larger than approximately 1.0 µm tend to aggregate under physiological conditions 
and be retained mechanically by capillaries, resulting in rapid uptake by tissue-resident 
phagocytic cells and high accumulation in the liver, spleen, and, to a lesser extent, in the 
bone marrow (50). Thus, when the particle size falls between 20 nm and 1 µm, clearance 
mechanisms are minimized, and circulation time is greatly prolonged (43). Intracellularly, 
particle size has been shown to mediate the efficiency of cross presentation of exogenous 
antigens by DCs (51). Phagocytosed 50 nm particles with antigen bound to them were found 
to be shuttled to an acidic environment within 30 min of phagocytosis, and the antigen was 
inefficiently cross presented. Antigen bound to 500 nm and 3 µm beads was found not to be 
trafficked to an acidic environment in the cell and, thus, had increased efficiency in peptide 
processing and cross presentation onto MHC (major histocompatibility complex) class I 
molecules. The effect of this was stimulation of a cytotoxic CD8+ T cell response (rather 
than the default CD4+ T response for exogenously delivered antigen), which is often needed 
for viral infections, antitumor immunity, or surveillance (51). Thus, the size of antigen 
carriers also has a critical role in biodistribution, cellular uptake, and the intracellular 
trafficking of antigen for determining the type of immune response (humoral or cytotoxic).
Surface chemistry, such as the charge of particles, also has a significant role in the 
intracellular and extracellular processing of particles. Recently, Babensee and coworkers 
(52) showed that the charge of a carrier can enhance DC maturation in response to 
glycoconjugates (Figure 2e). In this study, it was shown that the conjugate charge induced 
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the second largest increase in proinflammatory DC maturation, falling behind only ligand 
density in potency (52). It has also been shown that the surface charge of NPs influences the 
adsorption of opsonins (and other plasma proteins), leading to macrophage recognition, 
which is followed by phagocytosis and elimination (53). Despite conflicts in the literature 
about how charge directly affects circulation times and processing by cells, a general 
consensus has been reached that the absolute value of the zeta potential may be the most 
important factor for the phagocytosis of NPs (43). Virtually all reports have found that 
macrophage uptake increases as the surface charge increases (that is, either a positive or 
negative zeta potential) (54, 55). Further, NPs that are neutral at physiological pH avoid 
uptake by phagocytic cells, thereby exhibiting markedly delayed blood clearance (56--58). 
Chemical composition at the surface of NPs also alters the quantity of protein adsorbed, the 
kinetics of protein adsorption, and cellular trafficking (59, 60). These factors have critical 
roles in the physiological filtering of the particle to the lymph, spleen, or liver, or toward 
targeted moieties. The adsorbed biolayer further promotes or suppresses adhesion of the NPs 
to cell membranes, thereby influencing cellular uptake and processing, and the ultimate fate 
of the particle.
Another aspect of particle-surface chemistry is hydrophobicity, which is a key factor in 
opsonization. Hydrophobic particles in the body are preferentially coated by plasma proteins 
(e.g., immunoglobulin, complement, albumin) and then cleared by the reticuloendothelial 
system (61). Thus, most particulate-based systems have relied on hydrophilic coatings or 
modifications to reduce this passive mechanism of adsorption and clearance. The most 
popular modification is to coat particles with polyethylene glycol (PEG) to increase the 
surface hydrophilicity of the particle and thus reduce nonspecific protein adsorbance (58, 62, 
63). On the surface of NPs, PEG forms a dense network of hydrophilic chains that act as a 
steric barrier to plasma proteins and macrophages (63--65). PEGylated NPs have been 
shown to effectively reduce macrophage uptake in vitro and prolong circulation half-life in 
vivo, decrease the accumulation of NPs in the liver, and be cleared mainly by the spleen 
after a long residence in blood (66--68). The mechanism of the PEG coating on NPs and its 
effect on opsonization, biodistribution, and tumor-targeted delivery have been reviewed in 
many papers and, thus, are not further expounded upon here (69, 47).
Additionally, it has recently been shown that the modality of surface presentation of 
identical agents can alter the immune response. For example, glycan--bovine serum albumin 
constructs displayed from the surface of beads, from flat-well surfaces, or delivered in a 
range of soluble concentrations have been shown to differentially enhance DC maturation 
(71). Glycoconjugates presented from a nonphagocytosable flat-well surface showed the 
highest amount of DC maturation, and soluble conjugates showed the lowest. Interestingly, 
presentation of conjugates on phagocytosable beads showed an intermediate level of DC 
activation when compared with a soluble or nonphagocytosable presentation. These 
interactions were found to be receptor-specific and able to be inhibited by blocking 
antibodies. Further, chitin microparticle preparations in a phagocytosable size (1--10 µm), 
but not in soluble or nonphagocytosable sizes (40--100 µm), have been shown to induce 
activation of mitogen-activated protein kinase (MAPK) within macrophages in a manner 
dependent on TLR2, and to eventually induce high activation of M1 macrophages (72). It 
has also been shown that particulate antigens, but not soluble proteins, mediate follicular DC 
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activation of B cells, and that virus-like particles, and not their constitutive proteins, are 
efficiently transported to murine splenic follicular DCs (73). Taken together, these studies 
indicate that it is not only the material, surface interface, charge, and other biophysical 
properties of materials that can mediate the immune response but also the form in which 
these materials or constructs are delivered that can drive the immune response toward a 
desired outcome.
2.4. Controlled Release of Immunostimulatory Molecules
Controlling the release of immunostimulatory molecules (TLR ligands, cytokines, or 
chemokines) from particulate or scaffold biomaterial systems to enhance immune outcomes 
holds immense promise for future therapeutics. The use of liposomes, polymer NPs, and 
various hydrogel formulations combined with TLR ligands, cytokines, and chemokines has 
shown that the immune response can be directed toward a proinflammatory Th1, Th2, 
cytotoxic, or B cell-stimulating response, or a combination of these.
NPs are designed to act as effective carriers of adjuvant compounds in order to safely 
provide the inflammatory signals necessary for triggering immunity to coadministered 
antigens. Most classical adjuvants, such as alum, activate the NLRP3 inflammasome. 
Activation of the inflammasome requires the signaling of both TLRs and NLRP3 (74, 75) in 
antigen-presenting cells (APCs). Antigen-loaded PLGA NPs have been constructed to 
conjugate lipopolysaccharide (LPS) (76), CpG oligonucleotides (77), or 
poly(inosinic:cytidylic acid) (78) to their surface to stimulate TLRs while simultaneously 
engaging the NLRP3 receptors. It has been found that these particles produce potent CD4+ 
and CD8+ responses from T cells and that these responses can be used to promote potent 
immune responses to model antigens, e.g., OVA (78), and clinically relevant vaccines to 
murine West Nile encephalitis (76, 77). Mice inoculated with these NPs were found to have 
high amounts of systemic IL-1β, produce large and sustained amounts of antigen-specific 
IgG, and were found to have a nearly 100% protection rate when challenged with the 
pathogen (76, 77). However, these compounds are not ideal for clinical translation due to the 
pleiotropic effects and toxicity of LPS or CpG oligonucleotides. Other TLR ligands, such as 
MPLA for TLR4, have been included in clinical vaccine formulations (co-delivered with 
alum) (81).
Another approach to enhancing vaccination has been to use lipid bilayer particles to deliver 
antigens and adjuvants together to APCs (79, 80). Moon et al. (80) have shown that 
interbilayer-crosslinked multilamellar vesicles formed by crosslinking headgroups of 
adjacent lipid bilayers within multilamellar vesicles can form potent vaccines. These 
multilayered vesicles, utilizing monophosphoryl lipid A (MPLA) as an adjuvant, loaded 
with a model antigen (OVA) elicited robust antibody titers that were 1,000 times greater 
than those elicited by simple liposomes, and they triggered steadily increasing humoral and 
CD8 T cell responses with antigen-specific T cells expanding to a peak of nearly 30% of the 
total CD8 cell population (80).
In the absence of TLR ligands, the delivery of encapsulated proinflammatory cytokines, 
such as IFN-γ (82), IL-1α (83), IL-2 (84), and others (85--87), along with the antigen of 
interest, has also been pursued as a means of stimulating the immune system. Studies have 
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generally showed improved performance over that of particles not bearing cytokines. For 
example, polycyanoacrylate NPs loaded with tumor necrosis factor-α (TNF-α) showed a 
78% reduction over particles not bearing TNF-α in terms of tumor expansion when the 
particles were coadministered with tumor antigen. However, cytokine-loaded particles have 
shown little clinical efficacy as monotherapies (88), and, thus, more potent combinatorial 
approaches have recently been pursued.
During natural infections, mast cells deliver inflammatory cytokines to lymph nodes (LNs) 
via the release of inflammatory granules, NP complexes of heparin, cytokines, and other 
factors, which target these stimuli to the draining LNs. In an elegant biomimetic strategy, St. 
John et al. (89) packaged inflammatory cytokines (TNF-α or IL-12) in polyelectrolyte NPs 
mimicking mast cell granules (Figure 3). These synthetic granules were engineered by 
complexing heparin (the key cytokine-binding component of native mast cell granules) and 
chitosan together with cytokine cargos (Figure 3a and b); these granules effectively targeted 
minute quantities of cytokines to LNs following injection (Figure 3c). When used as a 
delivery vehicle for TNF-α during vaccination of mice with hemagglutinin from the 
influenza virus, these particles enhanced adaptive immune responses and increased the 
survival of mice during lethal challenge without toxicity (Figure 3d and e).
2.5. Delivering Anti-Inflammatory Immunomodulators
The studies above discuss proinflammatory immunomodulation of the immune system. 
However, in the treatment of autoimmune diseases caused by disorders of immune 
regulation, such as multiple sclerosis, psoriasis, rheumatoid arthritis, and type 1 diabetes, an 
ideal therapy should induce long-term durable antigen-specific T cell tolerance or immune 
suppression. Current therapeutic strategies based on T cell-specific peptides or antibodies 
cause various side effects, such as cytokine-release syndrome during monoclonal antibody 
treatment, and anaphylactic responses during peptide infusion, and have shown only 
marginal efficacy (90--92). Thus, using biomaterials to direct the immune system toward a 
tolerogenic response has been posited as an ideal vehicle for driving immune tolerance while 
mitigating unintended side effects. Recently, mycophenolic acid delivered by nanoliposome 
gels has been shown to significantly increase the survival time of lupus-prone mice even 
after the mice developed severe renal damage (93). The DCs that internalized gel particles 
produced a smaller quantity of inflammatory cytokines, such as IFN-γ and IL-12, which was 
thought to enhance survival in the mice (93). Similarly, in mice liposomes and polymeric 
dendrimers delivering glucocorticoids have been shown to suppress the production of 
inflammatory cytokines and reduce physiological indicators of rheumatoid arthritis and 
multiple sclerosis (94), effects also noted when delivered as plasmids encoding anti-
inflammatory proteins (95), or as peptide antigens (96). In another approach, researchers 
used PLGA NPs loaded with leukemia inhibitory factor, an IL-6 family protein that 
promotes Treg formulation and immune tolerance (97), to expand Foxp3+CD4+ T cell 
numbers in a nonhuman primate model in vitro, to downregulate Th17 development, and 
prolong survival of vascularized heart grafts in mice (98).
Immunoengineers are also harnessing the natural mechanisms induced by apoptotic cells, 
which often present their antigens in a tolerance-inducing manner (99, 100). Recently, it was 
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discovered that intravenous infusion of apoptotic cells that had been chemically conjugated 
with an autoantigen of relevance to reverse autoimmune disease were processed in vivo as a 
natural component of the apoptotic cells (101). To provide a more reliable and reproducible 
means of achieving the same effect, Miller and colleagues (102) recently demonstrated that 
intravenous administration of PLGA microparticles (500 nm in diameter) conjugated with 
encephalitogenic peptides targeted these antigens to splenic marginal-zone macrophages 
normally involved in the clearance of apoptotic cells, leading to successful induction of 
long-term T cell tolerance in mice with relapsing experimental autoimmune 
encephalomyelitis. Another approach has been to design NPs displaying peptide--MHC 
complexes of the targeted autoantigens, which can bind directly to T cells in vivo. Tsai et al. 
(103) showed that, unexpectedly, NPs coated with diabetes-related antigen and MHC 
complexes expanded cognate regulatory T cells in diabetic mice and suppressed the 
development of type 1 diabetes in prediabetic mice.
Combinatorial delivery approaches aimed at suppressing T cell activation and enhancing 
Treg differentiation have also recently been employed. Combinations of transforming 
growth factor (TGF)-β1, IL-2, and either rapamycin (104) or retinoic acid (89) have been 
shown to induce a Treg phenotype, and to suppress naive T cell proliferation and function, 
and are capable of inducing Foxp3+ Tregs in human cells. Both rapamycin and retinoic acid 
have been found to produce Tregs with similar functionality but with drastically different 
expression levels of CCR7, CCR9, and CCR10 (105), leading to significantly different 
migratory patterns and distributions in vivo (104). T cells treated with retinoic acid were 
found to home to mucosal tissues, and T cells treated with rapamycin homed toward 
lymphoid tissues. Interestingly, this homing led to differences in histological colitis scores in 
a Powrie murine model of T cell-mediated colitis: with rapamycin, Treg-treated mice were 
better able to reverse colitis than were Treg-treated mice with retinoic acid (104). Another 
combinatorial approach has been to co-deliver antigen with 2-(1′H-indole-3′-carbonyl)-
thiazole-4-carboxylic acid methyl ester (ITE), a small tolerance-inducing molecule used to 
suppress the immune response against the co-delivered antigen (106). In this study, the 
delivery of the ITE-loaded particles with an epitope from myelin oligodendrocyte 
glycoprotein caused an expansion of the Foxp3+ Treg compartment and suppressed the 
development of experimental autoimmune encephalomyelitis, an experimental model of 
multiple sclerosis (106). Finally, co-delivery of the immunosuppressive factors TGF-β1 and 
IL-10 in hydrogels has also been shown to deactivate bone marrow DCs and cause a 
significantly reduced ability for the DCs to stimulate T cells. This approach highlights the 
ability of intelligently designed biomaterials to orchestrate a downstream immune response 
by modulating the phenotype of immunomodulatory DCs (107).
3. BIOMATERIALS TARGETING IMMUNE CELLS AND LYMPHOID ORGANS
Engineered biomaterials are being designed and synthesized to target immunomodulators to 
lymphoid tissues or disease sites to manipulate the immune system for a variety of 
therapeutic applications, and especially to enhance vaccines. In this section, we discuss the 
design and application of biomaterials that target lymphatic tissue. This topic is too broad to 
exhaustively cover in a single section so instead, to provide an overview of directions in the 
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field, we highlight recent examples of biomaterials engineered for vaccine delivery and cell-
based immunotherapy.
3.1. Vaccine Delivery
Subunit vaccines consisting of recombinant protein or polysaccharide antigens delivered in 
tandem with molecular adjuvants using synthetic delivery systems could be attractive 
alternatives to live viral or bacterial vaccines, by combining low toxicity with an absence of 
antivector immunity. Rapid progress has been made in designing and synthesizing novel 
biomaterials, nanomaterials in particular, to carry both antigen and adjuvant, protect them 
from degradation in vivo, and deliver them to targeted lymphoid tissues, including LNs and 
mucosa-associated lymphoid tissues (e.g., lymphoid organs of the airways, gastrointestinal 
tract, and reproductive tract).
The LN is the anatomic location where naive T cells make contact with APC partners such 
as DCs (108), and the LNs contain a much higher concentration of DCs than peripheral 
tissues do. In addition, humoral immunity is initiated by B cells in LNs; B cells take up 
antigen directly in LN follicles to generate protective antibodies (109). Thus, both T cell and 
antibody responses require antigen and adjuvant to be delivered to LNs to efficiently induce 
primary immune responses.
Vaccines are typically injected intramuscularly or subcutaneously and must then reach LNs 
by draining through lymphatic vessels. A key factor regulating this convective transport is 
the size of the vaccine’s components because the extracellular matrix of connective tissues 
traps large particles. The role of particle size in LN targeting was elegantly demonstrated by 
the laboratories of Hubbell, Swartz and coworkers (110--112), which synthesized oxidation-
sensitive poly(propylene sulfide) NPs (PPS NPs) of well-defined sizes with covalently 
conjugated antigens to define the optimal particle sizes required for targeting vaccine 
antigens to DCs in LNs. These studies showed that 20 nm PPS NPs were more readily taken 
up into the lymphatics and retained in draining LNs for longer periods (up to 120 hours), 
compared to larger particles 100 nm in size. Moreover, up to 40--50% of resident LN DCs 
internalized 20 nm NPs. When conjugated with OVA, 25-nm polyhydroxylated-OVA NPs 
elicited similar levels of both cellular and humoral immunity as OVA injected with LPS, 
which is a very strong adjuvant compound with unacceptable toxicity for vaccine use. 
Similar conclusions about the optimal solid NP sizes for maximal LN uptake have been 
drawn by other studies using polystyrene NPs as model vaccine carriers (113, 114). Beyond 
tissue-level transport and delivery to LNs, particle size also has a role in determining the 
efficiency of uptake by DCs, with submicron-sized particles taken up by DCs more 
efficiently than larger particles (115).
Mucosa-associated lymphoid tissues---that is, lymphoid tissues draining mucosal surfaces---
are another important target for vaccine delivery. Vaccination through mucosal surfaces, 
such as the airways or reproductive tract, offers the possibility of needle-free administration, 
and mucosal immunity may be key for optimal protection against pathogens that invade 
through mucosal surfaces (116). However, mucosal surfaces present a series of barriers to 
vaccine absorption: vaccines are diluted in mucosal secretions, captured in mucus gels, 
attacked by proteases and nucleases, and excluded by epithelial barriers (116, 117). Using 
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the same PPS NP system described above, Nembrini et al. (118) showed that pulmonary 
administration of NPs can deliver antigen very effectively to DCs in the pulmonary 
parenchyma, promote highly efficient cross presentation, and induce potent protective 
mucosal and systemic CD8+ T cell immunity. When this NP system was applied to deliver a 
tuberculosis antigen (Ag85B) adjuvanted with CpG oligonucleotides, pulmonary vaccination 
led to enhanced induction of antigen-specific polyfunctional Th1 and Th17 responses, and 
protective efficacy against aerosolized Mycobacterium tuberculosis challenge when 
compared with soluble Ag85B with CpG or with the same formulation administered 
intradermally (119). The effective mucosal uptake of these PPS NP vaccines seems to agree 
well with work done to define the properties of particles required for mucus penetration. A 
series of detailed studies by the Hanes laboratory (120--122) has shown that particles with 
sizes less than 500 nm, dense PEGylation, and lacking overt charge are required for efficient 
diffusion through mucus. Efficient vaccination via NP vaccines in the lungs may also be 
facilitated in part by active uptake by macrophages and DCs that constitutively sample 
antigens across the mucosal barrier (123). Li et al. (124) showed that coadministration into 
the lungs of antigen-loaded lipid nanocapsules of approximately 200 nm in diameter 
together with TLR agonist adjuvants led to dramatically elevated antigen delivery to lung-
draining LNs (leading to 100% protection against pulmonary vaccinia virus challenge) when 
compared with the same vaccine components administered in soluble form (0% protection 
for the soluble vaccine). The accessibility of reproductive tract mucosa may enable 
additional strategies for vaccine delivery. For example, Kuo-Haller et al. (125) demonstrated 
that poly(ethylene-co-vinyl acetate) disks designed for insertion into vaginal mucosa could 
release protein vaccines for up to 2 weeks, leading to substantially enhanced mucosal IgG 
and IgA responses when compared with traditional parenteral vaccination.
3.2. Hitchhiking on Lymphocytes
Immunotherapy treatments aim to stimulate or augment a patient’s own immune system to 
attack cancer or infectious disease (126, 127). One of the most promising immunotherapy 
strategies undergoing clinical testing to treat cancer is adoptive cell therapy (ACT), in which 
ex vivo expanded, autologous antigen-specific T cells are infused into patients with 
advanced cancers or viral infections (128--130). However, a limitation of this approach is 
the decline in function of transplanted T cells after infusion, particularly in the setting of 
solid cancers where tumors actively suppress T cell effector functions. In order to maintain 
high numbers of functional tumor-specific cytotoxic T lymphocytes (CTLs), 
immunostimulatory agents, such as interleukin cytokines, are often coadministered with 
transferred cells. However, these adjuvant agents often exhibit severe dose-limiting 
toxicities (131, 132). To enhance the efficacy of adjuvant drugs during ACT while avoiding 
systemic toxicity, Stephan et al. (133) developed a novel strategy of piggybacking drug 
carriers loaded with supporting agents directly onto the T cells themselves. Adjuvant agent-
releasing lipid NPs were chemically conjugated to the plasma membrane of donor cells, 
enabling continuous pseudoautocrine stimulation of transferred T cells in vivo (Figure 4a). 
In a model of ACT for cancer, marked enhancements in tumor elimination were achieved 
using this strategy (Figure 4a). Using the same strategy it was further shown that small-
molecule drugs can be efficiently delivered into the T cell synapse, enhancing their 
therapeutic efficacy (134) (Figure 4b). In a related strategy aiming to alter the differentiation 
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fate of CD4+ T cells, the Fahmy group (98) reported on the design of NPs loaded with 
leukemia inhibitory factor or IL-6 and designed specifically to bind to helper T cells through 
functionalization with anti-CD4 antibodies. When mixed with donor lymphocytes just prior 
to infusion, these particles bound to CD4+ T cells and modulated their differentiation to 
promote tissue-graft survival or promote an increase in Tregs (98).
The ex vivo manipulation of cells is a clinically laborious and expensive therapy, but 
another alternative is to target supporting agents to T cells directly in vivo. Zheng et al. 
(135) demonstrated the possibility of direct in vivo targeting using cytokines or cell-specific 
antibodies as ligands to target PEGylated liposomes to therapeutic T cells, thus enabling 
repeated stimulation of ACT T cells (Figure 4c and d). The high efficiency of targeted NP 
binding to T cells as they recirculate in the blood suggests that this could be a 
straightforward strategy for modulating the function of immune cells.
4. BUILDING LYMPHOID ORGAN STRUCTURES
4.1. Engineered Lymphoid Tissues
Cells of the immune system are generated in primary lymphoid organs (the thymus and bone 
marrow) and maintained or activated in secondary lymphoid organs (the spleen, LNs, and 
Peyer’s patches). Much as in other applications in regenerative medicine, biomaterials have 
been explored as scaffolds to create synthetic lymphoid organs in vivo and as platforms to 
generate functional lymphoid tissues in vitro (136, 137). In vivo synthetic lymphoid organs 
can be used as platforms to dissect critical cues in lymphoid tissue organogenesis or 
neogenesis, or to provide enhanced immune function in humanized mouse models, where 
the native murine lymphoid tissue exhibits structural or organizational defects due to the 
immunodeficient background of the animals during development, as well as incomplete 
crosstalk among mouse and human cytokines and receptors (138). In vitro models of 
lymphoid tissue can also be used for fundamental studies, and, further, could provide an 
important nonanimal model-based solution to preclinical toxicity testing of pharmaceutical 
agents and act as a screening tool for vaccine or drug development.
T cells differentiate from hematopoietic precursors in the thymus. Strategies to generate 
functional human T cells using in vitro mimics of the thymus have been pursued as models 
to enhance understanding of the fundamental biology of T cell differentiation and also as 
potential platforms for generating large numbers of therapeutic lymphocytes for treatments 
such as ACT in cancer. Pioneering work by the Scadden laboratory (139) first showed that 
porous 3D tantalum-coated carbon sponges could be used as a supporting scaffold for 
thymic stromal cells. In these studies, the addition of human hematopoietic precursor cells to 
scaffolds harboring murine thymic stroma led to the differentiation of nearly 80% of the 
seeded human cells into CD3+ T cells, a 2--3-fold increase in the frequency of T cell 
differentiation when compared with the use of 2D in vitro cultures. The lymphocytes that 
were generated expressed diverse T cell receptor-α and -β chains and responded 
appropriately to mitogenic stimuli in vitro. In pursuit of strategies to generate T cells in the 
absence of xenogeneic stromal cells, Taqvi et al. (140) reported using synthetic 
microspheres functionalized with recombinant notch ligands, which mimic key signals 
provided by stromal cells during thymocyte development. This approach may be able to be 
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combined with other biomaterials-based approaches to create fully synthetic thymic 
microenvironments.
Other groups have focused on engineering secondary lymphoid organs that could support 
functional immune responses in vivo or provide a model of human lymphoid tissue in vitro. 
One approach that is useful in the setting of vaccination is to use biomaterials to engineer 
the microenvironment of native LNs by injecting immunomodulating biomaterials 
intranodally---that is, directly into native lymphoid tissue. Jewell et al. (78) showed that 
biodegradable microparticles injected into peripheral LNs could disperse throughout the T-
and B zones of the tissue and release inflammatory stimuli to alter the activation state of 
DCs for approximately 1 week, thus significantly enhancing the response to vaccination. 
Alternatively, an exciting challenge would be to use biomaterials to support the 
organogenesis of de novo lymphoid organs. The development of secondary lymphoid organs 
depends on a complex set of orchestrated cellular and cytokine and chemokine cues, but, 
interestingly, lymphoid tissue neogenesis can also be triggered by ectopic expression or a 
single lymphoid cytokine or chemokine (141, 142). Building on such fundamental 
observations, Suematsu & Watanabe (143) showed that the implantation of macroporous 
collagen scaffolds seeded with lymphoid stromal cell lines engineered to express the key 
instructive cytokine lymphotoxin-α could lead to the spontaneous generation of complete 
lymphoid tissues in mice. These engineered tissues showed segregated accumulations of T 
cells and B cells in separate zones reminiscent of native LNs, as well as generation of the 
specialized endothelium of LNs (high endothelial venules) (143). Importantly, these 
engineered lymphoid organs were functional for T cell and B cell activation and could 
support antigen-specific immune responses in immunodeficient animals (143--145).
In vitro LN constructs generated from murine or all-human cell preparations have also been 
pursued. Giese et al. (146, 147) employed agarose gels or nonwoven polyamide fiber 
scaffolds as matrices for human T and B cells, and DCs that mimic the extremely high cell 
densities present in lymphoid tissues. These constructs have shown the ability to support 
antibody responses to licensed vaccines and physiologically relevant alterations in cytokine 
production in response to immunosuppressive drugs (146). Higbee et al. (148) developed a 
modular in vitro system termed MIMIC (Modular Immune In vitro Construct) with separate 
in vitro scaffolds representing peripheral tissues and LNs, and that aimed to predict the 
responses of cultured human leukocytes to vaccine administration or other biologicals. The 
lymphoid tissue module of this system was able to predict antibody responses measured in 
the blood of immunized individuals following tetanus vaccination.
The vigorous migration of lymphocytes is also a key part of LN physiology (149). To this 
end, composite scaffolds comprising ordered, macroporous PEG hydrogels infiltrated with 
fibrillar collagen matrix have been shown to support physiological lymphocyte migration 
between DCs adherent to the macroporous PEG support (150, 151). Chemokines promoting 
the robust migration of lymphocytes scanning for antigen in LNs are produced by the LN 
stroma (152). Tomei et al. (153) demonstrated that murine fibroblastic reticular cells, the 
stromal cells lining T cell areas of LNs, are induced to produce the key lymphoid chemokine 
CCL21 by exposure to 3D fluid flow. These various strategies, which aimed to recapitulate 
critical features of the LN microenvironment, have both provided new insights into the 
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physiology of lymphoid tissue and shown progress toward developing in vitro models of de 
novo immune reactions that might be used for screening vaccine or drug formulations.
4.2. Biomaterials as Vaccination Nodes for Immunization
The engineering strategies for biomaterials discussed above focus on the cells and tissue 
functions of primary lymphoid organs (where immune cells mature) and secondary 
lymphoid organs (where immune cells are activated) during immune responses. However, 
biomaterials can also be employed to shape events happening outside the lymphoid organs 
during the earliest stages of a nascent immune response. In these cases, investigators have 
pursued strategies using biomaterials as matrices to promote the attraction of APCs or their 
precursors, APC differentiation and activation, and loading with antigen to promote the 
immune response. Ali et al. (154, 155) developed an implantable PLGA sponge scaffold 
designed to regulate each of these steps through the sequential release of scaffold-embedded 
granulocyte--macrophage colony-stimulating factor (GM-CSF), CpG oligonucleotides 
complexed with polyethyleneimine, and tumor lysate. GM-CSF is a chemoattractant and 
differentiation factor for DC precursors. In these studies, scaffolds were designed to release 
this cytokine during 1--2 weeks to recruit and differentiate DCs in the scaffold. CpG and 
tumor lysate were largely retained in the scaffolds during this same time frame, allowing 
cells recruited to the implant to be activated (by the inflammatory CpG signal) and loaded 
with antigen (the tumor lysate). The activated and antigen-loaded cells then migrated to the 
draining LNs, leading to efficient priming of antitumor T cells (155). Interestingly, 
injections of microparticles releasing the same vaccine components were not effective when 
compared with the scaffold-based vaccine, but why the 3D scaffold structure may be 
important for this response remains to be determined. When compared with implants 
carrying only one factor or the other, GM-CSF- and CpG-loaded scaffolds elicited the 
highest accumulation of plasmacytoid DCs and CD8+ DCs (important for crosspresentation 
of antigen to CD8+ T cells), which correlated with greatly enhanced protection in a murine 
model of therapeutic vaccination for melanoma (154). Based on these impressive preclinical 
results, this scaffold-based vaccine is being rapidly moved forward into a small clinical trial 
of preventing melanoma at the Wyss Institute. (https://clinicaltrials.gov/ct2/show/
NCT01753089). Building on these results, Mooney and coworkers further developed 
injectable pore-forming 3D scaffolds that spontaneously assemble in vivo from mesoporous 
silica rods (MSRs) as an implant to shape the host immune cell response (Figure 5a) (156). 
When loaded with OVA, GM-CSF and CpG-ODN, this MSR-scaffold-based vaccine 
elicited potent immune serum antibody responses, and cytotoxic T cell responses that 
enhanced protection against OVA-expressing tumors (Figure 5b–d).
As noted above, Singh et al. (157) have also designed injectable PEG-based hydrogels 
carrying the DC attractant CCL20, and PLGA microspheres carrying antigen-encoding DNA 
and small interfering RNA against the suppressive cytokine IL-10. These composite gels 
attracted DCs, induced priming of antigen-specific T cells, and increased survival in a 
prophylactic model of vaccination against lymphoma (158). The synthetic immune priming 
center-based particles showed 45% more CD8+ CTL response and 53% stronger CD4+ CTL 
activity than naked DNA vaccine in mice, and tumor-challenged mice had a 40% survival 
rate (twice that of those receiving the naked DNA vaccine) (158). Similarly, mice inoculated 
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with a different antigen (hepatitis-B surface antigen) were shown to significantly switch 
their immune phenotype toward a Th1 response as evidenced by an increase in IFN-γ 
production and a decrease in IL-4 production by CD4+ T cells. This further led to enhanced 
antiviral CTL activity and higher murine survival (159).
Park et al. employed a multifunctional depot strategy with nanogels that simultaneously 
release tolerance inhibitors and pro-immunity cytokines (160) . To enhance the efficacy of 
tumor therapy, nanoliposomal polymeric gels were loaded with a TGF-β inhibitor and IL-2. 
These nanogels significantly delayed tumor growth, increased the survival of tumor-bearing 
mice to 100%, and increased the activity of natural killer cells and infiltration of 
intratumoral-activated CD8+ T cells (160). Another strategy for inducing immune responses 
against cancer relies on using synthetic matrices to surround an accessible tumor with 
immunostimulatory factors designed to attract and activate immune effectors to the tumor, 
with the goal of turning a tumor into its own vaccine. Hori et al. (161--163) developed self-
gelling alginate solutions composed of soluble alginate chains mixed with 
immunomodulatory factors (cytokines and adjuvants) and calcium-releasing alginate 
microspheres. When mixed and injected peritumorally in a mouse model of melanoma, 
calcium exchange from the microspheres led to gelation of alginate around established 
tumors. Peritumoral alginate matrices releasing a superagonist form of the potent 
immunostimulatory cytokine IL-15 (IL-15SA) concentrated the cytokine in the tumor during 
several days, whereas simple intratumoral injection of the same dose of IL-15 led to rapid 
clearance of the cytokine. This prolonged exposure to IL-15SA led to greatly increased 
levels of CD8+ T cells and reduced levels of Tregs in tumors, and cured approximately 60% 
of mice bearing B16F10 melanoma tumors (161). Altogether these approaches demonstrate 
that biomaterials can controllably orchestrate sequential steps leading to the induction of an 
optimal immune response, thus greatly enhancing the potency of vaccines and cancer 
immunotherapies.
5. SYNTHETIC ANTIGEN-PRESENTING CELLS
Bioconjugation approaches offer opportunities to control display parameters such as the 
form of presentation of immunomodulatory ligands, controlling the release of antigens, or 
controlling delivery of soluble immunomodulators. Such approaches have allowed complex 
immune synapses to be stripped down not only to elucidate their key components but also to 
engineer functionality through the properties of the materials used or display parameters. 
These approaches are supported by reports showing that the intensity of the T cell stimulus 
depends on the density of the bound receptors that are in contact with a surface (164, 165). 
The presence of high-density clusters has also been shown to accelerate T cell activation 
(164, 165). Further, in the LNs, APCs are thought to concentrate the presentation of T cell 
stimuli to enable effective immune responses, a process that is mimicked in the synthetic 
system (166). Using this idea, several immunomodulatory approaches have been attempted 
including carbon nanotube display of T cell agonists, multivalent polymeric presentation of 
immune stimulants, and artificial APCs designed for ex vivo and in vivo applications.
T cells have been stimulated ex vivo using single-walled carbon nanotube (SWNT) bundles 
presenting antibody stimuli (167). Studies have shown that SWNTs displaying a T cell-
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stimulating antibody (anti-CD3) induce potent activation of T cells due to the high density 
of antibody that is displayed from the surfaces of these complexes. Another approach 
utilized SWNTs to present MHC-1 via adsorbing neutrAvidin to the SWNT and then take 
biotinylated peptide-specific MHC-1 and display it from the SWNT. Using this approach, 
significant CD8+ T cell activation was seen along with an enhanced antigen-specific T cell 
response that was more than threefold higher than the soluble control in similar conditions 
(168). A different multimeric approach using poly(amido amine) dendrimers has been 
shown in a variety of studies to enhance immunity with increasing multivalency (169--173). 
For example, Fahmy et al (171) showed that plate-bound anti-CD3 immobilized by 
poly(amido amine) dendrimers and co-delivered with doxorubicin, a potent antimitogenic 
drug, was able to significantly bind and inhibit T cell proliferation.
Artificial immune-stimulating systems are an emerging technology that aims to induce 
therapeutic immunity without the need for autologous APCs. Steenblock et al. (174) loaded 
PLGA microparticles with IL-2 and then adsorbed anti-CD3 to the surface. They showed 
that CD8+ T cells were highly proliferative in response to the scaffold’s sustained release of 
IL-2, whereas the increase in CD4+ T cells was limited by apoptosis. They found that 
synaptic accumulation of IL-2 in the early stages of activation was important for activation, 
and that slow and sustained release of IL-2 was critical for expansion of the T cell 
population, whereas an initial short-lived burst of cytokines (on the order of hours) played 
no role in expansion of the population (174). In a mouse tumor model, a single injection at 
day 10 after tumor implantation of loaded particles releasing IL-2 and displaying anti-CD3 
and anti-CD28 significantly delayed the kinetics of tumor growth (175). A final approach to 
immune stimulation, based on immobilization of surface ligands, has been developed by 
Roy and coworkers (140). They differentiated stem cells into immunocompetent T cells 
using beads displaying synthetic notch ligands.
All of the approaches described above used either in vivo expansion and stimulation or ex 
vivo training and expansion of mature antigen-specific T cells. However, these approaches 
are not viable in patients for whom autologous T cells are not available (such as patients 
with lymphoma or those who are immune-deficient). For such patients, robust and 
reproducible in vitro generation of functional, transplantable T cells from embryonic stem or 
adult stem cells will be necessary (176). With this in mind, Roy and coworkers (140) 
functionalized magnetic microbeads with the notch ligand DLL4 using streptavidin--biotin 
binding and antibody--antigen coupling. Thy1.2+ early T cells were successfully generated 
from mouse bone marrow hematopoietic stem cells using DLL4 functionalized beads. In a 
similar approach, stem cells were differentiated into antigen-specific CD8+ human T cells 
using DLL1-coated plates and cytomegalovirus or human leukocyte antigen (HLA) A*201 
tetramers loaded with influenza A virus epitopes (176). The resultant T cell population was a 
polyclonal population that was specific for cytomegalovirus or influenza; additionally, these 
cells were found to exhibit cytolytic functionality against infected cells and to have high 
IFN-γ production and Granzyme B secretion (176).
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6. SYSTEMS APPROACHES
Systems biology combines high-content multiplexed measurements with statistical and 
computational modeling to elucidate biological functions and interrelationships at various 
scales. The temporal and spatial complexity of the events that lead to proinflammatory or 
tolerogenic immune responses have been increasingly found to involve complex signaling 
interactions that occur both intra- and intercellularly (177). Many important insights have 
emerged from studies that have focused on a single level of the hierarchy [for example, TLR 
signaling pathways in DCs (178), or paracrine cytokine signaling by T cells (179)], but such 
insights cannot offer a picture of cause and effect when immune cells are presented with 
complex biomaterial stimuli. This is due, in large part, to overlapping and competing 
signaling from membrane and intercellular receptors (180). As such, a systems biology 
approach to immunology has been proposed to help elucidate the intricate behavior of the 
immune system in response to biomaterials. Three different scales of immune response have 
been considered in reference to biomaterials: DNA and RNA expression, surface-marker 
expression and signaling, and secreted cytokines and chemokines.
Gene expression or RNA microarrays, or both, have recently been used to analyze the 
effects of a range of stimuli from biomaterials including carbon nanotubes (181, 182), 
substrates (183), and particulate biomaterials (184); foreign-body reactions have also been 
analyzed (185). Although these approaches utilize a method of analysis known as shot-gun 
genomics to determine the immune response to various biomaterials, many insights have 
been gained into the underlying mechanisms of what is happening in cells. For example 
Aldinucci et al. (182) showed that when DCs were placed on multiwalled carbon nanotubes 
the nanotubes affected DC gene regulation for functions such as focal adhesion, adherent 
junctions, actin organization, and the ability of DCs to properly reorganize the cytoskeleton 
upon LPS recognition. These findings have implications for the immune response noted by 
Fadel et al. (167, 168); and these results led researchers to study the behavior of the adherent 
DCs that were not properly rearranging their cytoskeleton and had decreases in endocytic 
processes (182).
Although DNA- and RNA-expression microarrays provide an excellent way to determine 
what is happening to a cell in terms of transcription, it has been confirmed many times and 
in multiple models that transcriptional activity does not necessarily directly relate to 
translational activity, which does not necessarily lead to functional protein expression or 
secretion. Thus, high-throughput strategies that assess functional outcomes (such as protein 
expression or secretion) have been developed. A high-throughput tool for assessing surface 
markers has been developed by Kou & Babensee (186); it looked at the fold change in CD86 
(proinflammatory) over DC-SIGN (constitutively expressed) surface markers on DCs to 
assess proinflammatory DC activation. This tool was then used to assess DC activation on a 
library of titanium surfaces (187), as well as to elucidate which molecular properties of a 
library of polymethacrylates (188) were associated with DC activation. Thus, with no a 
priori knowledge of a material’s properties and of immune activation, the researchers were 
able to develop a model that showed that biomaterial surface chemistry was most important 
in determining induced DC phenotypes. Specifically, surface oxygen content was associated 
with iDCs, and increased surface carbon was associated with enhanced DC maturation (187, 
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188). In these studies, secreted cytokines were also measured using a fairly high-throughput 
multiplexed cytokine secretion assay and a NanoDrop Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA). However, this method becomes prohibitively expensive for 
larger libraries of materials. Thus, Garcia-Cordero et al. (189) recently introduced, 
characterized, and applied a microfluidic technology platform for low-cost high-throughput 
quantitation of soluble proteins in various sample matrices. This platform was applied in the 
context of systems vaccinology to assess the synergistic production of inflammatory 
cytokines from DCs stimulated with 10 different adjuvants that target TLRs. With this 
system, they were able to measure in a mouse model six different cytokines simultaneously 
at four different time points in response to MPLA plus Gardiquimod (InvivoGen, San Diego, 
CA) and MPLA plus CpG-B in samples from bronchoalveolar lavage and in blood serum. 
Garcia-Cordero et al. found that their results agreed with the industry-standard ELISA 
(enzyme-linked immunosorbent assay), used 1,000 times less reagent, and could multiplex 
simultaneous measurements to a much higher degree than other assays. Reducing the 
necessary sample volume to a few nanoliters was key to decreasing the cost of reagents by 
more than three orders of magnitude and to being able to assess other high-throughput assay 
outputs, such as those developed by Kou et al.(186–189) Anderson and colleagues (190) 
have provided another important approach to combining surface-characterized polymer 
microarrays in a high-throughput manner to elucidate the relationships between surface 
structure and function that drive cellular interactions. All of the systems biology approaches 
described above utilized statistical modeling (principle component analysis (187), partial 
least squares regression (188), cluster analysis (18), or pathway signatures analysis (182)) to 
glean insights from massive data sets. It is necessary to combine rich quantitative 
experimental data and knowledge of biochemical or cellular parameters in order to gain 
knowledge from these data sets. The predicted outcomes from the models must then be 
tested at the bench to examine the strength of the underlying model. The models or 
questions that can be generated from computational analysis of large data sets can be used to 
inform experimental designs because it is from the accumulated data sets that correlations or 
predictions can be made. Furthermore, independently produced data sets that have some 
overlapping measurements can be combined mathematically to further expand the questions 
that can be addressed. It has been found that much more complete and informative models 
of immunological processes than those that are formulated purely by hypothesis-driven 
research or represented by simplified cartoons in reviews can be made by using iterative 
cycles of model building, simulation, prediction, experiment, and model refinement. This 
field of systems approaches to immunology and biomaterials is in its infancy, and it holds 
the potential to drive the development of the next generation of biomaterials and to foster a 
deeper understanding of underlying biological process and interactions between biomaterials 
and immune cells.
7. OUTLOOK AND CHALLENGES
As illustrated by the diverse examples provided here, the application of biomaterials as 
immunomodulating therapeutics and as model systems for studying fundamental 
immunology shows great promise. Rapid advances in this relatively new area of 
biomaterials research have been enabled by an integration of lessons learned during the past 
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15 years in other areas, such as drug delivery and regenerative medicine. The demonstration 
that biomaterials can be used to amplify or suppress immune responses has already been 
applied to models of infectious disease, cancer, and autoimmunity. However, a number of 
key challenges and areas for future work are ripe to be addressed.
One area where more can be done using biomaterials for immune modulation is in using 
synthetic materials as tools to dissect the rule set governing immune responses in vivo. For 
example, various attempts to determine how the kinetic pattern of exposure to antigen and 
inflammatory signals influences the induction of immunity during vaccination have been 
pursued using common tools in the vaccinologist’s toolbox, such as the administration of 
DNA vaccines to achieve prolonged antigen expression, or the administration of viral 
vectors with short versus long times to immune clearance. But such approaches are 
inherently constrained by the immune response itself, which directly governs the pattern of 
vaccine kinetics that are obtained through the elimination of antigen-expressing cells. 
Biomaterials that provide a defined pattern of antigen--adjuvant availability independent of 
ongoing inflammation or effector responses are already being designed (191, 192), and 
systematic studies of how parameters---such as the duration, magnitude, and temporal 
pattern of vaccine exposure---affect the magnitude, quality, and durability of immune 
memory are needed. A first step in this direction was taken by Pulendran and coworkers 
(193), who compared trivalent inactivated influenza vaccine and live, attenuated influenza 
vaccine in humans and mice. The trivalent vaccine induced higher antibody titers and more 
plasmablasts than the live, attenuated vaccine did. In humans given the trivalent vaccine, 
expression of the kinase CaMKIV at day 3 after vaccination was inversely correlated with 
later antibody titers and, thus, could be used as a predictive metric for vaccine efficacy 
(193). More recently, genomic analysis of the human immune response to the influenza 
vaccine showed that 20 genes exhibit a significant correlation with transcriptional immune 
responses and with downstream antibody responses (194). These results showed that 
variation at the level of genes involved in membrane trafficking and antigen processing 
significantly influences the human response to influenza vaccination, and that the 
transcriptional response could be used as a correlate for downstream vaccine efficacy. More 
such studies could provide valuable guidance to the vaccine field at large, irrespective of 
their individual potential for translation directly into viable vaccine platforms.
A second area for future work, which is closely linked to the first, is to better define how 
synthetic biomaterials intrinsically modulate innate immunity and adaptive responses. 
Recent studies focusing on how classic adjuvants, such as alum and other foreign materials, 
interact with the immune system likely have relevance to determining how other synthetic 
biomaterials may stimulate host molecular sensors of danger and damage (195--197). Such 
insights could open up new avenues for developing safe and inexpensive strategies to 
modulate host immunity in vaccines and immunotherapies.
Finally, the overarching goal of most biomaterials research is to develop new materials that 
can be translated to clinical use. As with the development of any new type of biomedical 
intervention, this is a costly process with a high rate of failure, and it often requires a 
transfer of basic research findings to commercial entities capable of carrying out the 
necessary development and manufacturing scale-up to prepare clinical-grade materials. 
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However, academic collaborations between biomaterials researchers and clinicians may 
provide a second route for clinical translation, as illustrated by the ongoing Wyss Institute-
funded Phase I trial of implantable vaccine scaffolds (discussed in Section 4). Such 
translational efforts will be aided by the recognition of key areas of need and opportunity. 
For example, cancer immunotherapy, after more than 20 years of preclinical and clinical 
studies that showed much promise but little clinical success, has now begun to show clear 
clinical results, and multiple ongoing trials of immunomodulatory drugs have demonstrated 
that the immune system can attack and destroy metastatic cancer even in heavily pretreated 
patients with advanced cancer (198--200). Biomaterials-based immunotherapies that can 
further enhance the efficacy or reduce the toxicity of these immunomodulatory strategies 
will be well positioned to capitalize on the renewed sense of promise in the field of cancer 
immunotherapy (201).
As highlighted in this review, much of the recent work in immune-stimulating biomaterials 
has focused on developing novel vaccine strategies and cancer immunotherapies, but many 
opportunities remain beyond these applications, in which the ability of biomaterials to 
regulate the immune system can have an impact on both basic immunology and disease 
therapy. Although most vaccine studies have addressed infectious diseases and cancer, much 
less attention has focused on vaccination strategies promoting tolerance, which could have 
an impact on autoimmune diseases such as multiple sclerosis. Biomaterials designed to 
promote tolerance may also have a role to play in solving problems in transplant rejection, 
and debilitating, chronic graft-versus-host disease. Biomaterials should also have an 
expanded role as tools for modeling or mimicking the human immune system to improve 
our understanding of human immunity. For example, biomaterials approaches from 
regenerative medicine may have an important part to play in creating improved human tissue 
microenvironments in humanized mouse models of infectious disease and cancer to allow a 
bridge to be built between the utility of small animal models and the predictive power of 
human clinical studies.
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Figure 1. 
(a–c) Overview of interactions of different types and structures of biomaterials with the 
immune system. Abbreviations: Ig, immunoglobulin; IL-10, interleukin-10; MPLA, 
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monophosphoryl lipid A; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic) acid; 
PRR, pattern recognition receptor; TGF-β, transforming growth factor-β; TLR, Toll-like 
receptor; lymph, lymph node; conj., conjugated.
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Figure 2. 
Nano- or microparticle engineering for immune outcomes. (a) Scanning electron microscope 
and transmission electron microscope (inset) images of budding and spherical polystyrene-
b-poly(ethylene oxide) microparticles. (b) Confocal microscopy images of macrophage-
associated (red) budding and spherical particles, (green) lysosomes, (blue) nuclei. (c--d) 
Particle-induced neutrophil recruitment (c) and interleukin (IL)-1β cytokine secretion (d) 
depends on surface curvature. (e) Dendritic cell (DC) inflammatory maturation factor (IMF) 
levels in response to glycoconjugate adsorbed to wells with different surface properties. The 
molar ratio of thiolated glycan to bovine serum albumin (BSA) is indicated. The isoelectric 
point (pI) of glycoconjugates of BSAwas scaled from a pI of ~4.0 to ~10.0 using 
ethylenediamine (EDA). NC-BSA: no EDA added; L-BSA: 0.05 M EDA, low pI; M-BSA: 
0.15 M EDA, medium pI; H-BSA: 0.90 M EDA, high pI. (Panels a--d adapted with 
permission from 41; panel e adapted with permission from 52.)
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Figure 3. 
Synthetic mast cell (MC) granules for targeted vaccination. (a) Scanning electron 
microscope micrograph of an activated rat peritoneal MC (natural) and a synthetic particle 
consisting of heparin and chitosan (synthetic). (b) Diagram demonstrating the modeling of 
synthetic particles after MC granules, where chitosan, made positively charged under acidic 
conditions, is substituted for MC proteases, enabling inflammatory mediators to be 
entrapped within a similar matrix structure containing heparin. (c) Lymph node (LN) 
sections after injection of saline, particles containing poly-L-lysine conjugated to the 
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fluorochrome fluorescein isothiocyanate (PLL-FITC) (pFITC, green) or soluble PLL-FITC 
(sFITC, green). These LNs were isolated 45 minutes post-injection, sectioned, and stained 
for B cells (B220, red) and LN sinuses (Lyve-1, blue). (d) Day 21 geometric mean titers for 
total immunoglobulin (Ig) G after vaccination with haemagglutinin in combination with the 
designated adjuvants, with a boost at day 14. (e) Synthetic particles containing tumor 
necrosis factor (TNF) (pTNF) or the positive control, alum, increased the survival of mice 
challenged with influenza significantly over naive mice, antigenalone controls or soluble 
TNF (sTNF). (Adapted with permission from 89.)
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Figure 4. 
Hitchhiking on lymphocytes. (a) Tumor-specific Pmel-1 T cells conjugated with 
interleukin-15 superagonist (IL-15Sa) and IL-21-releasing nanoparticles (NPs) robustly 
proliferate in vivo and eradicate established B16 murine melanomas. Dual, longitudinal, in 
vivo bioluminescence imaging shows the growth of Gaussia luciferase--expressing B16F10 
tumors and click beetle red luciferase--expressing T cells. Flow cytometry plots show the 
frequencies of Vβ13+CD8+ tumor-specific T cells recovered from pooled lymph nodes of 
representative mice 16 days after T cell transfer. (b, left) Schematic view of strategy to 
modulate T cell responses via nanoparticle conjugation to membrane proteins: Surface-
conjugated drug-loaded nanoparticles slowly release their cargo compounds, which locally 
permeate the plasma membrane and block molecules in the cytosol that dampen T cell 
activation. (Right) 3D reconstruction of confocal microscopy images showing CD8+ effector 
T cells (carboxyfluorescein succinimidyl ester stain shown in blue) immediately after 
conjugation with fluorescent, multilamellar lipid vesicles (yellow). (c) Schematic of T cell--
targeted immunoliposome preparation. IL-2-Fc and anti-Thy1.1 F(ab′)2 were mildly reduced 
by dithiothreitol (DTT) to expose hinge region free thiols (-SH) for reaction with the 
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liposome maleimide functional headgroups. (d) Quantification of percentages of endogenous 
or transferred T cells labeled by day 0 or day 3 liposome (Lip) injections in the blood. (Panel 
a adapted with permission from 133; panel b adapted with permission from 134; panels c 
and d adapted with permission from 135.)
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Figure 5. 
Injectable and spontaneously assembling scaffolds consisting of mesoporous silica rods 
(MSRs) modulate immune cells in vivo and increase vaccine efficacy. (a) A schematic 
representation of in vivo spontaneous assembly of MSRs and recruitment of host cells for 
maturation. PBS: phosphate-buffered saline. (b) Enzyme-linked immunosorbent assay 
(ELISA) analysis of serum ovalbumin (OVA)- specific immunoglobulin (Ig) G2a titers after 
immunization with, respectively, soluble components of the vaccine (bolus vaccine), MSRs 
loaded with OVA, or MSR vaccine. (c) Number of tetramer+ CD8+ T cells in spleen 7 days 
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after vaccination with blank MSR (labeled Blank) or complete MSR vaccine (labeled 
Vaccine). (d) Survival rate after subcutaneous injection of various vaccine formulations 10 
days before EG.7-OVA tumor inoculation. (Adapted with permission from 156.)
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